Referencia número: HY-15097

Myricetin

Name: Myricetin
Brand: MedChemExpress
SKU: HY-15097
Price: 66.00 USD
Availability: InStock
Rating: 5 (30 reviews)

(Synonyms: Cannabiscetin)

30 Cited Publications

Revisión del cliente

Based on 30 publication(s) in Google Scholar

Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 98.68%
No. CAS: 529-44-2
Fòrmula: C₁₅H₁₀O₈
Peso molecular:318.24

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Myricetin Chemical Structure

No. CAS: 529-44-2

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (30)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.

Ver todos los productos específicos de isoformas PI3K :

Ver todos los productos específicos de isoformas Endogenous Metabolite :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	14.8 mg/mL Compound: 23	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 15568778]
BV-2	IC₅₀	>100 μM Compound: 2	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction	[PMID: 27623545]
CWR22R	IC₅₀	13.1 μM Compound: 13	Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer	[PMID: 22789812]
H9	EC₅₀	35 μM Compound: 16	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	69 μM Compound: 16	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
HCT-116	IC₅₀	>20 μM Compound: Myricetin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HCT-116	IC₅₀	23 μM Compound: 3	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	24 μM Compound: 3	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	28.2 μM Compound: 206b	Cytotoxicity against human HCT116 cells assessed as reduction in cell growth by WST-1 assay Cytotoxicity against human HCT116 cells assessed as reduction in cell growth by WST-1 assay	[PMID: 30917303]
HCT-116	IC₅₀	4.1 μM Compound: 3	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay	[PMID: 22212721]
HEK293	IC₅₀	>10 μM Compound: 23	Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay	[PMID: 30943030]
HepG2	IC₅₀	>20 μM Compound: Myricetin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HK-2	IC₅₀	>20 μM Compound: Myricetin	Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HT-29	EC₅₀	3.02 μM Compound: Myricetin	Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay	[PMID: 24900447]
HT-29	IC₅₀	>20 μM Compound: Myricetin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HT-29	IC₅₀	2.12 μM Compound: Myricetin	Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins	[PMID: 24900447]
Huh-7	CC₅₀	>50 μM Compound: 28	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	46.9 μM Compound: 28	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Jurkat	IC₅₀	10 μM Compound: Myricetin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	12 μM Compound: Myricetin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
KB	ED₅₀	15 μg/mL Compound: NSC-407290	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]
L02	IC₅₀	>20 μM Compound: Myricetin	Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
L929	EC₅₀	55 μM Compound: myricetin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining	[PMID: 9287415]
L929	EC₅₀	59 μM Compound: myricetin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay	[PMID: 9287415]
MCF7	IC₅₀	>20 μM Compound: Myricetin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
MCF7	IC₅₀	4.7 mg/mL Compound: 23	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 15568778]
MV4-11	GI₅₀	>50 μM Compound: 7	Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
Peritoneal macrophage	IC₅₀	99 μM Compound: kp22	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
RAW264.7	IC₅₀	19.2 μM Compound: 98	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA	[PMID: 37683361]
RAW264.7	IC₅₀	19.7 μM Compound: 98	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA	[PMID: 37683361]
RAW264.7	IC₅₀	23.9 μM Compound: 98	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA	[PMID: 37683361]
RS4-11	GI₅₀	>50 μM Compound: 7	Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
SK-BR-3	IC₅₀	>100 μM Compound: 4	Induction of apoptosis in human SKBR3 cells assessed as PARP cleavage by Western blotting analysis Induction of apoptosis in human SKBR3 cells assessed as PARP cleavage by Western blotting analysis	[PMID: 24548207]
SK-BR-3	IC₅₀	>100 μM Compound: 4	Inhibition of Hsp70 in human SKBR3 cells assessed as HER2 protein degradation by Western blotting analysis Inhibition of Hsp70 in human SKBR3 cells assessed as HER2 protein degradation by Western blotting analysis	[PMID: 24548207]
SK-BR-3	IC₅₀	>100 μM Compound: 4	Inhibition of Hsp70 in human SKBR3 cells assessed as RAF1 protein degradation by Western blotting analysis Inhibition of Hsp70 in human SKBR3 cells assessed as RAF1 protein degradation by Western blotting analysis	[PMID: 24548207]
SK-BR-3	IC₅₀	13.5 μM Compound: 4	Displacement of GM-cy3B from Hsp90 in human SKBR3 cells after 24 hrs by fluorescence polarization assay Displacement of GM-cy3B from Hsp90 in human SKBR3 cells after 24 hrs by fluorescence polarization assay	[PMID: 24548207]
U2OS	EC₅₀	14.7 μM Compound: Myricetin	Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay	[PMID: 24900447]
Vero C1008	CC₅₀	>200 μM Compound: 87	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell growth incubated for 24 hrs by WST-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell growth incubated for 24 hrs by WST-8 assay	[PMID: 37597436]

In Vitro

Myricetin exhibits the scavenging activity towards a number of radicals and ions. It displays poor activity (IC₅₀ value=1.4 mg/mL) in a superoxide dismutase (SOD)-like activity assay^[1]. It prevents cancer cell death via apoptosis via regulation of PI3K/Akt and MAPK signalling pathways^[2].
Myricetin exhibits antiphotoaging effects by quenching causative free radicals in the skin. Myricetin is able to suppress UVB-induced COX-2 expression in mouse skin epidermal JB6 P+ cells. It inhibits UVB-induced initiation of activator protein-1 and NF-κβ, as well as Fyn kinase activity^[1].
Myricetin inhibits viability of SKOV3 ovarian cancer cells in a dose-dependent manner. It induces DNA DSBs and ER stress, which leads to apoptosis in SKOV3 cells^[3].
Myricetin inhibits human Hsp70 by more than 80% with IC₅₀ values of 83, 11 and 12 μM, respectively^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Treatment of orthotopic pancreatic tumors with myricetin results in tumor regression and decreases metastatic spread^[2]. Exposure to 150 μM myricetin causes 14%, 26%, 5% and 49% inhibition of rabbit platelet aggregation, induced by ADP, arachidonic acid, collagen and PAF, respectively^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 529-44-2
Appearance Solid
Peso molecular 318.24
Fòrmula C₁₅H₁₀O₈
Color Light yellow to yellow
SMILES

OC1=CC(O)=C(C(C(O)=C(C2=CC(O)=C(O)C(O)=C2)O3)=O)C3=C1
Synonyms

Cannabiscetin
Structure Classification
- Flavonoids
- Flavonols
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (30)

All Bio/Physico-chemical AssayIn Vivo Efficacy StudyHistological Imaging/StainingIHCFlow CytometryWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nat Commun

Nanomaterial signatures program biomolecular condensates via triphasic separation for chemoplasticity remodeling. [Abstract]

2025 Oct 29;16(1):9554. PMID: 41162367

Myricetin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Oct 29;16(1):9554. [Abstract]

Myricetin (50 μM, 3 h). Analysis of G3BP1 condensation extent in cells received SGs disassembly inhibitor in the presence.
ACS Nano

Emerging of Ultrafine Membraneless Organelles as the Missing Piece of Nanostress: Mechanism of Biogenesis and Implications at Multilevels. [Abstract]

2025 Feb 11;19(5):5659-5679. PMID: 39882824
Cancer Lett

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. [Abstract]

2025 Aug 29:633:218010. PMID: 40886822
Phytomedicine

Myricetin stabilizes PINK1 to activate mitophagy and ameliorate metabolic dysfunction-associated steatotic liver disease. [Abstract]

2026 Jun:155:158009. PMID: 41935459
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Apoptosis

BACH2 ameliorates cell apoptosis and autophagy as a molecular switch of BCL-2/Beclin-1 complex in myocardial infarction. [Abstract]

2026 Mar 15;31(3):100. PMID: 41838190
Cell Rep

Carvedilol sensitizes chemotherapy by targeting STING to boost anti-tumor immunity. [Abstract]

2025 Apr 16;44(5):115572. PMID: 40249703
J Agric Food Chem

Myricetin Induces Ferroptosis and Inhibits Gastric Cancer Progression by Targeting NOX4. [Abstract]

2024 Mar 27;72(12):6178-6188. PMID: 38483540
Eur J Med Chem

Usnic acid derivatives as tau-aggregation and neuroinflammation inhibitors. [Abstract]

2020 Feb 1:187:111961. PMID: 31865017
Biochem Pharmacol

Insight into the structure, function and the tumor suppression effect of gasdermin E. [Abstract]

2024 Aug:226:116348. PMID: 38852642
Pharmaceuticals (Basel)

Myricetin Attenuates IMQ-Induced Psoriatic Inflammation Through Multi-Target Modulation: Evidence from Network Pharmacology and Experimental Validation. [Abstract]

2025 Nov 26;18(12):1802. PMID: 41471291

Myricetin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Nov 26;18(12):1802. [Abstract]

Myricetin (Myr; 0.5%-2%; Apply ointment). Scoring curves of back skin thickness, scaling, and erythema (PASI).

Myricetin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Nov 26;18(12):1802. [Abstract]

Myricetin (Myr; 0.5%-2%; Apply ointment). HE staining of skin sections.

Myricetin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Nov 26;18(12):1802. [Abstract]

Myricetin (Myr; 0.5%-2%; Apply ointment). IHC staining for K1, K16 and S100A9.

Myricetin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Nov 26;18(12):1802. [Abstract]

Myricetin (Myr; 0.5%-2%; Apply ointment). Flow cytometry analysis of IL-17A producing CD4+ T cells in the splenocytes.

Myricetin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Nov 26;18(12):1802. [Abstract]

Myricetin (Myr; 0.5%-2%; Apply ointment). Western blot analysis of EGFR and AKT in IMQ-induced mouse model.
Int Immunopharmacol

Activation of Nrf2/HO-1 signal with Myricetin for attenuating ECM degradation in human chondrocytes and ameliorating the murine osteoarthritis. [Abstract]

2019 Oct:75:105742. PMID: 31325727
Front Pharmacol

Myricetin Induces Autophagy and Cell Cycle Arrest of HCC by Inhibiting MARCH1-Regulated Stat3 and p38 MAPK Signaling Pathways. [Abstract]

2021 Oct 18;12:709526. PMID: 34733155
J Enzyme Inhib Med Chem

Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro. [Abstract]

2021 Dec;36(1):497-503. PMID: 33491508
Toxicology

NOX4/Keap1/Nrf2/ROS signaling drives ferroptosis in trimethyltin chloride-induced cardiac developmental malformations. [Abstract]

2026 Mar:521:154394. PMID: 41485541
ACS Omega

Unveiling Natural Power: Morin and Myricetin as Potent Inhibitors of Histidinol-Phosphate Aminotransferase in Drug-Resistant Acinetobacter baumannii. [Abstract]

2025 Feb 20;10(8):7920-7936. PMID: 40060852
Nanoscale

Targeted GSH-exhausting and hydroxyl radical self-producing manganese-silica nanomissiles for MRI guided ferroptotic cancer therapy. [Abstract]

2020 Aug 20;12(32):16738-16754. PMID: 32578659
Pestic Biochem Physiol

Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]

2025 Dec:215:106655. PMID: 41162045
Microbiol Spectr

Therapeutic potential of flavonols in the treatment of JCPyV. [Abstract]

2025 Aug 21:e0152725. PMID: 40838703
Arch Biochem Biophys

Myricetin attenuates lipopolysaccharide-induced acute lung injury by suppressing pyroptosis via activation of the Nrf2/HO-1/NQO1 signaling pathway. [Abstract]

2026 May 16:110848. PMID: 42144067
Mol Biol Rep

The beneficial effects of dose-dependent myricetin application on renal ischemia and reperfusion injury in a rat model. [Abstract]

2025 Sep 16;52(1):905. PMID: 40956366
3 Biotech

Selective blockade of IL-21 by myricetin impedes T follicular helper cell differentiation by negatively regulating the JAK/STAT/Bcl-6 pathway in a rheumatoid arthritis animal model. [Abstract]

2024 Jan;14(1):25. PMID: 38164247
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
DNA Cell Biol

Targeting FEN1 Suppresses the Proliferation of Chronic Myeloid Leukemia Cells Through Regulating Alternative End-Joining Pathways. [Abstract]

2021 Aug;40(8):1101-1111. PMID: 34156283
Biochem Biophys Res Commun

Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]

2018 Sep 3;503(1):297-303. PMID: 29890135
FEMS Microbiol Lett

In vitro enzyme characterization and several inhibitors for monkeypox virus core protease I7L. [Abstract]

2025 Jan 10:372:fnaf008. PMID: 39824654
Biochem Genet

Myricetin Restores Autophagy to Attenuate Lumbar Intervertebral Disk Degeneration Via Negative Regulation of the JAK2/STAT3 Pathway. [Abstract]

2025 Jun;63(3):2743-2759. PMID: 38842745
Folia Histochem Cytobiol

Myricetin alleviates H2O2-induced senescence and apoptosis in rat nucleus pulposus-derived mesenchymal stem cells. [Abstract]

2023;61(2):98-108. PMID: 37435897
bioRxiv

2020 Apr.

Solvente y solubilidad

In Vitro:

DMSO : ≥ 31 mg/mL (97.41 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 28.57 mg/mL (89.78 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1423 mL

15.7114 mL

31.4228 mL

5 mM

0.6285 mL

3.1423 mL

6.2846 mL

10 mM

0.3142 mL

1.5711 mL

3.1423 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[2]

Pancreatic cancer cells (MIA PaCa-2, Panc-1 or S2-013) or normal pancreatic ductal cells (PDCs) are treated with myricetin (12.5–200 μM). Cell viability is determined using the Dojindo Cell Counting Kit-8. Cells are seeded onto a 96-well plate at 1×10⁴ cells per well and allowed to adhere overnight. After treatment with myricetin at various concentrations for 24 hours, 10 μL of the tetrazolium substrate is added to each well of the plate. Plates are incubated at 37°C for 1 hour, after which the absorbance at 450 nm is measured^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice: Mice are given daily intraperitoneal injections of myricetin (30mg/kg in the MIA PaCa-2 model and 50mg/kg in the S2-013 model) or vehicle (DMSO) for 35 days (MIA PaCa-2 model) or 18 days (S2-013 model). Ultrasound measurements are performed at regular intervals to monitor tumor growth. At the end of the in vivo experiment, tumor size is measured using calipers and tumor volume is calculated^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Semwal DK, et al. Myricetin: A Dietary Molecule with Diverse Biological Activities. Nutrients. 2016 Feb 16;8(2):90. [Content Brief]

[2]. Phillips PA, et al. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of thephosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett. 2011 Sep 28;308(2):181-8. [Content Brief]

[3]. Xu Y, et al. Myricetin induces apoptosis via endoplasmic reticulum stress and DNA double-strand breaks in human ovarian cancer cells. Mol Med Rep. 2016 Mar;13(3):2094-100. [Content Brief]

[4]. Jinwal UK, et al. Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability. J Neurosci. 2009 Sep 30;29(39):12079-88. [Content Brief]

[5]. Tzeng SH, et al. Inhibition of platelet aggregation by some flavonoids. Thromb Res. 1991 Oct 1;64(1):91-100. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	3.1423 mL	15.7114 mL	31.4228 mL	78.5571 mL
	5 mM	0.6285 mL	3.1423 mL	6.2846 mL	15.7114 mL
	10 mM	0.3142 mL	1.5711 mL	3.1423 mL	7.8557 mL
	15 mM	0.2095 mL	1.0474 mL	2.0949 mL	5.2371 mL
	20 mM	0.1571 mL	0.7856 mL	1.5711 mL	3.9279 mL
	25 mM	0.1257 mL	0.6285 mL	1.2569 mL	3.1423 mL
	30 mM	0.1047 mL	0.5237 mL	1.0474 mL	2.6186 mL
	40 mM	0.0786 mL	0.3928 mL	0.7856 mL	1.9639 mL
	50 mM	0.0628 mL	0.3142 mL	0.6285 mL	1.5711 mL
	60 mM	0.0524 mL	0.2619 mL	0.5237 mL	1.3093 mL
	80 mM	0.0393 mL	0.1964 mL	0.3928 mL	0.9820 mL

Bioz

Keywords

Myricetin

30 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Myricetin

Publications Citing Use of MedChemExpress (MCE) Myricetin

Ver todos los productos específicos de isoformas PI3K

Ver todos los productos específicos de isoformas Endogenous Metabolite